Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182133 | 0.83 | RAB9A (0.52) | ALDH1A1RAB9ANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL304452 | 0.82 | RAB9A (0.55) | ALDH1A1RAB9ANPC1KDM4ESMN1; SMN2 | |
| Potassium SCHEMBL6997235 | 0.81 | RAB9A (0.53) | ALDH1A1RAB9ANPC1KDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5760483 | 0.81 | RAB9A (0.53) | ALDH1A1RAB9ANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL3106474 | 0.81 | RAB9A (0.53) | ALDH1A1RAB9ANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL6444116 | 0.81 | RAB9A (0.53) | ALDH1A1RAB9ANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL4182138 | 0.79 | CARM1 (0.53) | ALDH1A1RAB9ANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL7378382 | 0.79 | CARM1 (0.53) | ALDH1A1RAB9ANPC1SMN1; SMN2CA12 | |
| SCHEMBL13889650 | 0.78 | KMT2A (0.55) | ALDH1A1RAB9ANPC1KDM4ESMN1; SMN2 | |
| SCHEMBL8919406 | 0.78 | RAB9A (0.50) | ALDH1A1RAB9ANPC1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225120-A1 | Dihydropyridine soft drugs, and related compositions and methods | DODD JOHN H (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1192163-B1 | DITHIEPINO 6,5-b]PYRIDINES, AND RELATED COMPOSITIONS AND METHODS | ORTHO MCNEIL PHARM INC (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6562824-B2 | Calcium channel blockers; cardiovascular disorders; side effect reduction | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-05-13 | — | — | US | disclosed |
| EP-1296990-A2 | DIHYDROPYRIDINE COMPOUNDS FOR THE INHIBITION OF CALCIUM-INFLUX | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020133018-A1 | Dihydropyridine soft drugs, and related compositions and methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-09-19 | — | — | US | disclosed |
| US-20020103376-A1 | Dithiepino[6,5-b]pyridines, and related compositions and methods | BULLINGTON JAMES L (US) | 2002-08-01 | — | — | US | disclosed |
| EP-1192163-A1 | DITHIEPINO 6,5-b]PYRIDINES, AND RELATED COMPOSITIONS AND METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-20020032332-A1 | Dithiepino[6,5-b]pyridines, and related compositions and methods | BULLINGTON JAMES L (US) | 2002-03-14 | — | — | US | disclosed |
| US-20020026051-A1 | Dithiepino [6,5-b]pyridines, and related compositions and methods | BULLINGTON JAMES L (US) | 2002-02-28 | — | — | US | disclosed |
| WO-2001092267-A2 | DIHYDROPYRIDINE COMPOUNDS FOR THE INHIBITION OF CALCIUM-INFLUX | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| US-6291454-B1 | CALCIUM CHANNEL ANTAGONISTS WITH CARDIOVASCULAR, ANTIASTHINATIC AND ANTIBRONCHOCONSTRICTION ACTIVITY. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000077009-A1 | DITHIEPINO[6,5-b]PYRIDINES, AND RELATED COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225120-A1 | Dihydropyridine soft drugs, and related compositions and methods | CACNA1E, KCNN4, ATP2A1 | ALDH1A1 710/4885RAB9A 648/4885NPC1 3483/4885 |
| US-20020103376-A1 | Dithiepino[6,5-b]pyridines, and related compositions and methods | TRPV5, QDPR, TRPV6 | ALDH1A1 1492/4885RAB9A 2056/4885NPC1 4825/4885 |
| US-20020026051-A1 | Dithiepino [6,5-b]pyridines, and related compositions and methods | TRPV5, QDPR, TRPV6 | ALDH1A1 1492/4885RAB9A 2056/4885NPC1 4825/4885 |
| US-20020032332-A1 | Dithiepino[6,5-b]pyridines, and related compositions and methods | TRPV5, QDPR, TRPV6 | ALDH1A1 1492/4885RAB9A 2056/4885NPC1 4825/4885 |
| US-20020133018-A1 | Dihydropyridine soft drugs, and related compositions and methods | CACNA1E, ATP2A1, CACNA1D | ALDH1A1 833/4885RAB9A 579/4885NPC1 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.